JAK2 and carcinoma: In a monocentric study from 1994 to 2021, published by Colaizzo et al. (13), JAK2 p.V617F was found in 29.8% by systematic screening of 152 patients at the time of diagnosis of SVT without concomitant cirrhosis or carcinoma.